theraLASE®
Destroying Cancer at the Speed of Light™

Commercializing the next standard of care for bladder cancer



Study Drug (Ruvidar™) instilled in bladder intravesically



Ruvidar™ preferentially absorbed by bladder cancer cells



Study Device (green laser light) activates Ruvidar™ producing singlet oxygen which destroys the cancer cells



Bladder cancer cells destroyed, leaving healthy cells intact

Theralase® is safer and more effective than all currently FDA approved drugs

Company/ FDA Approved Drug (Date of Approval)	Number of Patients	Initial Complete Response ("CR")	Durable CR (15 months)	Pros	Cons	Cost ($USD 000s)	Market Capitalization ($USD)
International Bladder Cancer Group (IBCG) Guidelines for FDA Approval	**N/A**	**50%**	**25%**	**N/A**	**N/A**	**N/A**	**Bladder Cancer treatment market > $4 Billion**
Theralase® Ruvidar™ (Estimated for 2026)	68 /100	63% CR (71% TR)	34% (36% TR)	High initial efficacy. 56% of patients achieve CR after only 1 procedure. High duration of efficacy at 15 months.	Not currently FDA approved	$Unknown (Single treatment)	**$30 Million**
Merck Pembrolizumab (Keytruda) (2020)	96	40%	18.9%	First immunotherapy drug approved for BCG-Unresponsive NMIBC CIS.	Patients must have PD-L1 expression to generate a response. applicable to 20 to 40% of patient population. Associated with serious adverse events.	$300 (every 3 weeks for 24 months)	$327 Billion
Ferring Adstiladrin (2023)	98	51%	23.5%	First intravesical oncologic virus approved for BCG -Unresponsive NMIBC CIS.	Response of 3.9% CR at 24 months.	$159 to $262 (once every 3 months) $60 per installation	Private company; latest Annual Net Income > $300 Million
Immunity Bio BCG + Anktiva (Approved 04/2024 based on IBCG guidelines)	77	62%	36% (12month; 24 month 25%)	High initial efficacy and duration of efficacy.	Combinational product with standard of care BCG. Unknown contribution of BCG in patients. Concerns with number of treatments whether insurance will pay.	$Unknown (15 to 24 weekly treatments for up to 37 months)	$4.5 Billion

Mechanism of Action



Regulatory Timeline

Milestone	2019	2020	2021	2022	2023	2024	2025	2026
100 Patients Enrolled and Provided Primary Study Treatment (Projected)								
FDA Fast Track Designation (Actual)								
Breakthrough Designation (Projected)								
Patient Follow Up (Projected)								
Premarket Approval (Study Device) (Projected)								
Data Lock / Clinical Study Report Submission (Projected)								
Health Canada and FDA Marketing Approval (Projected)								
Commercialization Phase (Projected)								

Note: Theralase® and pier results sources can be found on Theralase Corporate Presentation: www.theralase.com